Figure 1
UBQLN2 insolubility is increased in Parkinson’s disease human tissue and mouse models. (A,B) Western blots of lysates from post-mortem cingulate cortex of PD and DLB patients show an increase in insoluble UBQLN2 in (A) PD (n = 8) and (B) DLB (n = 10) compared to age-matched controls. S PBS soluble, I PBS insoluble/sarkosyl soluble. (C) Representative western blot of whole brain lysate from mice overexpressing human mutant α-syn A53T solubilized in sarkosyl (n = 8) shows elevated levels of insoluble UBQLN2 compared to non-transgenic controls (n = 3). Western blots were cropped to focus on protein(s) of interest. Uncropped Western blots are shown in Supplemental Figure S1.
